Loxo@Lilly Oncology Medical
@LoxoLillyOnc
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK
ID:1508847230924562432
https://www.lilly.com/contact-us 29-03-2022 16:43:22
261 Tweets
5,1K Followers
633 Following
Follow People
Now Published in #npjBCancer , analyses from the monarchE study evaluating the impact of dose reductions on efficacy of a CDK 4/6 inhibitor in HR+, HER2-, high-risk #EarlyBreastCancer . #bcsm #BreastCancer #ClinicalTrials
See the publication here: e.lilly/4abbZC9
~30% of patients with high-risk, HR+, HER2- #EarlyBreastCancer experience disease recurrence within 5 years.
Recognizing high-risk features is important for optimizing #AdjuvantTherapy .
Learn more about high-risk features: e.lilly/4aO5aY2
#BCSM #BreastCancer #Oncology
Beginning at diagnosis, #BreastCancer impacts all aspects of patients’ lives.
Understanding and managing these long-term impacts is critical for supporting patients during treatment and throughout #survivorship .
Click here to learn more: e.lilly/49tUD2S
#AACR24 attendees - Thank you to everyone who joined us in San Diego and online! #CancerResearch
Visit the Loxo@Lilly congress hub to see the research we presented at this year’s meeting: e.lilly/3vt6MY4
#ClinicalTrials #KRAS #Nectin4 #SMARCA2
At #AACR24 , in collaboration with Foghorn Therapeutics, we’re excited to share the first presentation of preclinical data for an oral BRM (SMARCA2) selective inhibitor.
See the analysis here: e.lilly/3PGkyxo
#CancerResearch #PrecisionMedicine #SMARCA2
#AACR24 | Poster Presentation
Preclinical analysis of an orally administered, non-covalent, #KRAS G12D inhibitor that is selective against wild-type (WT) #KRAS .
View the presentation here: e.lilly/3PItAtz
#CancerResearch
#AACR24 - Learn about the EXCEED trial, a phase 1 trial investigating a #Nectin4 targeted antibody drug conjugate (ADC) in advanced or metastatic urothelial cancer and other solid tumors.
Trial in progress poster: e.lilly/3IWpuKx
#CancerResearch #ClinicalTrials #ADCs
A #BreastCancer Survivor describes a person who is anywhere along the trajectory from #BreastCancer diagnosis throughout their life. Addressing survivors’ long-term needs is critical for providing quality healthcare.
Learn more here: e.lilly/4ayFTjY
#Survivorship #BCSM
Advances in #PrecisionMedicine underscore the importance of #ComprehensiveGenomicProfiling (CGP) as standard of care for patients with #cancer .
Hear from Dr. Brandon Sheffield about the benefits of CGP and the advantages of insourcing biomarker testing: e.lilly/3PrFKqA
Thank you to all those who joined us at #ELCC24 !
Visit the Loxo@Lilly congress hub to see the research we presented in RET fusion-positive non-small cell lung cancer: e.lilly/4ajw0a4
#PrecisonMedicine #LCSM #NSCLC #CancerResearch
At #ELCC24 : Final analysis from the LIBRETTO-001 trial, evaluating a RET kinase inhibitor in patients w/ RET fusion-positive non-small cell lung cancer ( #NSCLC ).
See the data here: e.lilly/3vfzLOS
#PrecisionMedicine #LungCancer #LCSM
For patients with #EarlyBreastCancer on oral #AdjuvantTherapy , proactive, individualized decisions regarding treatment duration and dose modifications are important to ensure best possible clinical outcomes.
Click here to learn more: e.lilly/43v43Ke
#BCSM #BreastCancer
At #ELCC24 , check out our poster presentation to learn about continued treatment w/ a RET kinase inhibitor beyond progression in RET fusion-positive non-small cell #lungcancer (NSCLC).
Results from the LIBRETTO-001 trial: e.lilly/4a5I3rQ
#PrecisionMedicine #NSCLC #LCSM
At #ELCC24 , we're presenting additional analysis from LIBRETTO-001, a phase I/II study of a RET kinase inhibitor in patients with RET fusion-positive #NSCLC .
Learn more about our presentations at this year's meeting: e.lilly/4ajw0a4
#LungCancer #LCSM #CancerResearch
The EXCEED Trial | NOW ENROLLING
Phase 1 trial of our investigational #Nectin4 targeted antibody drug conjugate (ADC) in recurrent, advanced or metastatic solid tumors. #CancerResearch #ClinicalTrials #ADCs
Click here for detailed trial/enrollment info: e.lilly/49kkcUX
#BreastCancer mortality has, in general, ⬇ by 58% in the last 50 yrs, largely due to improved tx options for stages I-III.
To maximize #EarlyBreastCancer (EBC) outcomes, supporting patients throughout the entire treatment journey is vital.
Learn more: e.lilly/3Vk6hdb